CPT2 and cancer: Studies have found that many of the key mediators of FAO, such as CD36, CPT1 (including CPT1A, CPT1B and CPT1C) and CPT2 [48–50], are overexpressed in a variety of malignant tumors, and FAO has been found to be enhanced in a variety of cancers.